Chapter 18
Cell-Based Therapies for Canine Cancer
Nicola J. Mason,
M. Kazim Panjwani,
Nicola J. Mason
School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA
Search for more papers by this authorM. Kazim Panjwani
School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA
Search for more papers by this authorNicola J. Mason,
M. Kazim Panjwani,
Nicola J. Mason
School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA
Search for more papers by this authorM. Kazim Panjwani
School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA
Search for more papers by this authorBook Editor(s):Laurence J. N. Cooper MD, PhD,
Elizabeth A. Mittendorf MD, PhD,
Judy Moyes MB, BChir, FRCP(C), FRCPCH,
Sabitha Prabhakaran PhD,
Laurence J. N. Cooper MD, PhD
Search for more papers by this authorElizabeth A. Mittendorf MD, PhD
Search for more papers by this authorJudy Moyes MB, BChir, FRCP(C), FRCPCH
Search for more papers by this authorSabitha Prabhakaran PhD
Search for more papers by this authorFirst published: 14 February 2018
Summary
Pet dogs develop spontaneous cancers that have similar clinical, biological, and molecular features as human cancers. These tumors exhibit nonsynonymous, potentially immunogenic somatic mutations and arise in immunologically intact individuals, where they evade immune recognition and develop an immunosuppressive microenvironment. As such, canine cancer patients present comparable challenges to effective cell-based immunotherapies as their human counterparts and are beginning to be recognized as a valuable, unparalleled addition to preclinical mouse models for testing the safety and therapeutic efficacy of next-generation cell-based immunotherapies. Using a comparative approach, development of the best cell-based strategies can be accelerated and informative correlative data can be obtained that will direct patient selection and treatment paradigms, improving health care for both species.
References
- Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech. 2008; 1(2–3): 78–82.
- Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014; 6(2): 114–8.
- Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11): 991–8.
- Zarour HM. Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin Cancer Res. 2016; 22(8): 1856–64.
- Gordon I, Paoloni M, Mazcko C, Khanna C. The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med. 2009; 6(10): e1000161.
- Knapp DW, Waters DJ. Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans. Mol Med Today. 1997; 3(1): 8–11.
- Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer. 2008; 8(2): 147–56.
- Breen M, Modiano JF. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans: man and his best friend share more than companionship. Chromosome Res. 2008; 16(1): 145–54.
- Song SJ, Lauber C, Costello EK, Lozupone CA, Humphrey G, Berg-Lyons D, et al. Cohabiting family members share microbiota with one another and with their dogs. Elife. 2013; 2: e00458.
- Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015; 350(6264): 1084–9.
- Ivanov, II, Honda K. Intestinal commensal microbes as immune modulators. Cell Host Microbe. 2012; 12(4): 496–508.
- Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, et al. Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res. 2014; 20(16): 4200–9.
- Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39(1): 1–10.
- Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012; 72(5): 1081–91.
- Engelhorn ME, Guevara-Patino JA, Noffz G, Hooper AT, Lou O, Gold JS, et al. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat Med. 2006; 12(2): 198–206.
- Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015; 520(7549): 692–6.
- Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012; 482(7385): 400–4.
- Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014; 344(6184): 641–5.
- Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515(7528): 577–81.
- Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230): 124–8.
- Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. New England Journal of Medicine. 2014; 371(23): 2189–99.
- Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015; 350(6257): 207–11.
- Elvers I, Turner-Maier J, Swofford R, Koltookian M, Johnson J, Stewart C, et al. Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background. Genome Res. 2015; 25(11): 1634–45.
- de Miranda NF, Georgiou K, Chen L, Wu C, Gao Z, Zaravinos A, et al. Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. Blood. 2014; 124(16): 2544–53.
- Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012; 109(10): 3879–84.
- Decker B, Parker HG, Dhawan D, Kwon EM, Karlins E, Davis BW, et al. Homologous mutation to human BRAF V600E Is common in naturally occurring canine bladder cancer: evidence for a relevant model system and urine-based diagnostic test. Mol Cancer Res. 2015; 13(6): 993–1002.
- London CA, Galli SJ, Yuuki T, Hu ZQ, Helfand SC, Geissler EN. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol. 1999; 27(4): 689–97.
- Barth SM, Schreitmuller CM, Proehl F, Oehl K, Lumpp LM, Kowalewski DJ, et al. Characterization of the canine MHC class I DLA-88*50101 peptide binding motif as a prerequisite for canine T cell immunotherapy. PLoS One. 2016; 11(11): e0167017.
- Pinho SS, Carvalho S, Cabral J, Reis CA, Gartner F. Canine tumors: a spontaneous animal model of human carcinogenesis. Transl Res. 2012; 159(3): 165–72.
- Mitchell L, Dow SW, Slansky JE, Biller BJ. Induction of remission results in spontaneous enhancement of anti-tumor cytotoxic T-lymphocyte activity in dogs with B cell lymphoma. Vet Immunol Immunopathol. 2012; 145(3–4): 597–603.
- Goulart MR, Pluhar GE, Ohlfest JR. Identification of myeloid derived suppressor cells in dogs with naturally occurring cancer. PLoS One. 2012; 7(3): e33274.
- Sherger M, Kisseberth W, London C, Olivo-Marston S, Papenfuss TL. Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs. BMC Vet Res. 2012; 8: 209.
- Estrela-Lima A, Araujo MS, Costa-Neto JM, Teixeira-Carvalho A, Barrouin-Melo SM, Cardoso SV, et al. Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates. BMC Cancer. 2010; 10: 256.
- Fortuna L, Relf J, Chang YM, Hibbert A, Martineau HM, Garden OA. Prevalence of FoxP3(+) cells in canine tumours and lymph nodes correlates positively with glucose transporter 1 expression. J Comp Pathol. 2016; 155(2–3): 171–80.
- Itoh H, Horiuchi Y, Nagasaki T, Sakonju I, Kakuta T, Fukushima U, et al. Evaluation of immunological status in tumor-bearing dogs. Vet Immunol Immunopathol. 2009; 132(2–4): 85–90.
- Mucha J, Majchrzak K, Taciak B, Hellmen E, Krol M. MDSCs mediate angiogenesis and predispose canine mammary tumor cells for metastasis via IL-28/IL-28RA (IFN-lambda) signaling. PLoS One. 2014; 9(7): e103249.
- O'Neill K, Guth A, Biller B, Elmslie R, Dow S. Changes in regulatory T cells in dogs with cancer and associations with tumor type. J Vet Intern Med. 2009; 23(4): 875–81.
- Pinheiro D, Chang YM, Bryant H, Szladovits B, Dalessandri T, Davison LJ, et al. Dissecting the regulatory microenvironment of a large animal model of non-Hodgkin lymphoma: evidence of a negative prognostic impact of FOXP3+ T cells in canine B cell lymphoma. PLoS One. 2014; 9(8): e105027.
- Raposo T, Gregorio H, Pires I, Prada J, Queiroga FL. Prognostic value of tumour-associated macrophages in canine mammary tumours. Vet Comp Oncol. 2014; 12(1): 10–9.
- Tagawa M, Maekawa N, Konnai S, Takagi S. Evaluation of costimulatory molecules in peripheral blood lymphocytes of canine patients with histiocytic sarcoma. PLoS One. 2016; 11(2): e0150030.
- Watabe A, Fukumoto S, Komatsu T, Endo Y, Kadosawa T. Alterations of lymphocyte subpopulations in healthy dogs with aging and in dogs with cancer. Vet Immunol Immunopathol. 2011; 142(3–4): 189–200.
- Hartley G, Faulhaber E, Caldwell A, Coy J, Kurihara J, Guth A, et al. Immune regulation of canine tumour and macrophage PD-L1 expression. Vet Comp Oncol. 2016.
- Maekawa N, Konnai S, Ikebuchi R, Okagawa T, Adachi M, Takagi S, et al. Expression of PD-L1 on canine tumor cells and enhancement of IFN-gamma production from tumor-infiltrating cells by PD-L1 blockade. PLoS One. 2014; 9(6): e98415.
- Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011; 3(95):95ra73.
- Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8): 725–33.
- Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16): 1509–18.
- Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013; 5(177):177ra38.
- Newick K, O'Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors. Annu Rev Med. 2016.
- Abken H. Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors. Immunotherapy. 2015; 7(5): 535–44.
- Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006; 24(13): e20–2.
- Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013; 1: 26–31.
- Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010; 18(4): 843–51.
- Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16): 1507–17.
- Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25.
- Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015; 7(303):303ra139.
- Panjwani MK, Smith JB, Schutsky K, Gnanandarajah J, O'Connor CM, Powell DJ, Jr., et al. Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma. Mol Ther. 2016; 24(9): 1602–14.
- Mata M, Vera JF, Gerken C, Rooney CM, Miller T, Pfent C, et al. Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells. J Immunother. 2014; 37(8): 407–15.
- O'Connor CM, Sheppard S, Hartline CA, Huls H, Johnson M, Palla SL, et al. Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep. 2012; 2: 249.
- Hoshino Y, Takagi S, Osaki T, Okumura M, Fujinaga T. Phenotypic analysis and effects of sequential administration of activated canine lymphocytes on healthy beagles. J Vet Med Sci. 2008; 70(6): 581–8.
- Itoh H, Kakuta T, Kudo T, Sakonju I, Hohdatsu T, Ebina T, et al. Bulk cultures of canine peripheral blood lymphocytes with solid phase anti-CD3 antibody and recombinant interleukin-2 for use in immunotherapy. J Vet Med Sci. 2003; 65(3): 329–33.
- Mie K, Shimada T, Akiyoshi H, Hayashi A, Ohashi F. Change in peripheral blood lymphocyte count in dogs following adoptive immunotherapy using lymphokine-activated T killer cells combined with palliative tumor resection. Vet Immunol Immunopathol. 2016; 177: 58–63.
- Suhoski MM, Golovina TN, Aqui NA, Tai VC, Varela-Rohena A, Milone MC, et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther. 2007; 15(5): 981–8.
- Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016; 127(9): 1117–27.
- Biller BJ, Guth A, Burton JH, Dow SW. Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. J Vet Intern Med. 2010; 24(5): 1118–23.
- Whiteside TL. Apoptosis of immune cells in the tumor microenvironment and peripheral circulation of patients with cancer: implications for immunotherapy. Vaccine. 2002; 20 Suppl 4: A46–51.
- Curran KJ, Seinstra BA, Nikhamin Y, Yeh R, Usachenko Y, van Leeuwen DG, et al. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther. 2015; 23(4): 769–78.
- Stroncek DF, Ren J, Lee DW, Tran M, Frodigh SE, Sabatino M, et al. Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells. Cytotherapy. 2016; 18(7): 893–901.
- Wunderli PS, Felsburg PJ. An improved method for the isolation of enriched canine peripheral blood mononuclear cell and peripheral blood lymphocyte preparations. Vet Immunol Immunopathol. 1989; 20(4): 335–44.
- Lupu M, Gooley T, Zellmer E, Graves SS, Storb R. Principles of peripheral blood mononuclear cell apheresis in a preclinical canine model of hematopoietic cell transplantation. J Vet Intern Med. 2008; 22(1): 74–82.
- Mata M, Gottschalk S. Man's best friend: utilizing naturally occurring tumors in dogs to improve chimeric antigen receptor T-cell therapy for human cancers. Mol Ther. 2016; 24(9): 1511–2.
- Ting-De Ravin SS, Kennedy DR, Naumann N, Kennedy JS, Choi U, Hartnett BJ, et al. Correction of canine X-linked severe combined immunodeficiency by in vivo retroviral gene therapy. Blood. 2006; 107(8): 3091–7.
- Kennedy DR, Hartnett BJ, Kennedy JS, Vernau W, Moore PF, O'Malley T, et al. Ex vivo gamma-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency and the development of a thymic T cell lymphoma. Vet Immunol Immunopathol. 2011; 142(1–2): 36–48.
- Horn PA, Keyser KA, Peterson LJ, Neff T, Thomasson BM, Thompson J, et al. Efficient lentiviral gene transfer to canine repopulating cells using an overnight transduction protocol. Blood. 2004; 103(10): 3710–6.
- Neff T, Gerull S, Peterson LJ, Kiem HP. Improved short-term engraftment of lentivirally versus gammaretrovirally transduced allogeneic canine repopulating cells. J Gene Med. 2007; 9(5): 357–61.
- Panjwani MK. Modeling anti-CD20 chimeric antigen receptor therapy in canine B cell lymphoma patients. Seattle, WA: American Association of Immunologists; 2016.
- Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013; 21(4): 904–12.
- Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013; 122(6): 863–71.
- Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010; 24(6): 1160–70.
- Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013; 1(1): 26–31.
- Kiem HP, Allen J, Trobridge G, Olson E, Keyser K, Peterson L, et al. Foamy-virus-mediated gene transfer to canine repopulating cells. Blood. 2007; 109(1): 65–70.
- O'Connor CM. Chimeric antigen receptor T-cell therapy for companion canines with spontaneous B-cell non-Hodgkin lymphoma. Mol Ther. 2013; 21:S249.
- Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2016.
- Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005; 105(8): 3051–7.
- Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, et al. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2015; 38(1): 24–36.
- Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, et al. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother. 2010; 59(11): 1739–44.
- Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother. 2010; 59(12): 1781–9.
- Dillman RO, Duma CM, Ellis RA, Cornforth AN, Schiltz PM, Sharp SL, et al. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother. 2009; 32(9): 914–9.
- Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013; 73(6): 1777–86.
- Topfer K, Cartellieri M, Michen S, Wiedemuth R, Muller N, Lindemann D, et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol. 2015; 194(7): 3201–12.
- Phillips JH, Hori T, Nagler A, Bhat N, Spits H, Lanier LL. Ontogeny of human natural killer (NK) cells: fetal NK cells mediate cytolytic function and express cytoplasmic CD3 epsilon,delta proteins. J Exp Med. 1992; 175(4): 1055–66.
- Huang YC, Hung SW, Jan TR, Liao KW, Cheng CH, Wang YS, et al. CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells. J Leukoc Biol. 2008; 84(6): 1501–10.
- Lin YC, Huang YC, Wang YS, Juang RH, Liao KW, Chu RM. Canine CD8 T cells showing NK cytotoxic activity express mRNAs for NK cell-associated surface molecules. Vet Immunol Immunopathol. 2010; 133(2–4): 144–53.
- Shin DJ, Park JY, Jang YY, Lee JJ, Lee YK, Shin MG, et al. Ex vivo expansion of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cells. Vet Immunol Immunopathol. 2013; 153(3–4): 249–59.
- Foltz JA, Somanchi SS, Yang Y, Aquino-Lopez A, Bishop EE, Lee DA. NCR1 Expression identifies canine natural killer cell subsets with phenotypic similarity to human natural killer cells. Front Immunol. 2016; 7: 521.
- Rutgen BC, Konig R, Hammer SE, Groiss S, Saalmuller A, Schwendenwein I. Composition of lymphocyte subpopulations in normal canine lymph nodes. Vet Clin Pathol. 2015; 44(1): 58–69.
- Saalmuller A, Lunney JK, Daubenberger C, Davis W, Fischer U, Gobel TW, et al. Summary of the animal homologue section of HLDA8. Cell Immunol. 2005; 236(1–2): 51–8.
- Grondahl-Rosado C, Bonsdorff TB, Brun-Hansen HC, Storset AK. NCR1+ cells in dogs show phenotypic characteristics of natural killer cells. Vet Res Commun. 2015; 39(1): 19–30.
- Canter RJ. Combination radioimmunotherapy with adoptive NK transfer targets cancer stem cells in canine models of bone and soft tissue sarcoma. J Immunother Cancer. 2015; 3(Suppl2):P4.
- Mielcarek M, Sandmaier BM, Maloney DG, Maris M, McSweeney PA, Woolfrey A, et al. Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives. J Clin Immunol. 2002; 22(2): 70–4.
- Sokolic RA, Bauer TR, Gu YC, Hai M, Tuschong LM, Burkholder T, et al. Nonmyeloablative conditioning with busulfan before matched littermate bone marrow transplantation results in reversal of the disease phenotype in canine leukocyte adhesion deficiency. Biol Blood Marrow Transplant. 2005; 11(10): 755–63.
- Panse JP, Storb R, Storer B, Santos EB, Wentzel C, Sandmaier BM. Prolonged allogeneic marrow engraftment following nonmyeloablative conditioning using 100 cGy total body irradiation and pentostatin before and pharmacological immunosuppression after transplantation. Transplantation. 2005; 80(10): 1518–21.
- Barquinero J, Kiem HP, von Kalle C, Darovsky B, Goehle S, Graham T, et al. Myelosuppressive conditioning improves autologous engraftment of genetically marked hematopoietic repopulating cells in dogs. Blood. 1995; 85(5): 1195–201.
- Appelbaum FR, Deeg HJ, Storb R, Graham TC, Charrier K, Bensinger W. Cure of malignant lymphoma in dogs with peripheral blood stem cell transplantation. Transplantation. 1986; 42(1): 19–22.
- Willcox JL, Pruitt A, Suter SE. Autologous peripheral blood hematopoietic cell transplantation in dogs with B-cell lymphoma. J Vet Intern Med. 2012; 26(5): 1155–63.
- Feinstein L, Sandmaier B, Maloney D, McSweeney PA, Maris M, Flowers C, et al. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Ann N Y Acad Sci. 2001; 938: 328–37; discussion 37–9.
- Schuening F, Storb R, Goehle S, Meyer J, Graham TC, Deeg HJ, et al. Facilitation of engraftment of DLA-nonidentical marrow by treatment of recipients with monoclonal antibody directed against marrow cells surviving radiation. Transplantation. 1987; 44(5): 607–13.
- Bauer TR, Jr., Hai M, Tuschong LM, Burkholder TH, Gu YC, Sokolic RA, et al. Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy. Blood. 2006; 108(10): 3313–20.
- Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016; 8(355):355ra116.
- Xiong W, Candolfi M, Liu C, Muhammad AK, Yagiz K, Puntel M, et al. Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial. PLoS One. 2010; 5(6): e11074.
- Mito K, Sugiura K, Ueda K, Hori T, Akazawa T, Yamate J, et al. IFN{gamma} markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models. Cancer Res. 2010; 70(18): 7093–101.
- Tamura K, Arai H, Ueno E, Saito C, Yagihara H, Isotani M, et al. Comparison of dendritic cell-mediated immune responses among canine malignant cells. J Vet Med Sci. 2007; 69(9): 925–30.
- Bird RC, Deinnocentes P, Lenz S, Thacker EE, Curiel DT, Smith BF. An allogeneic hybrid-cell fusion vaccine against canine mammary cancer. Vet Immunol Immunopathol. 2008; 123(3–4): 289–304.
- Bird RC, Deinnocentes P, Church Bird AE, van Ginkel FW, Lindquist J, Smith BF. An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine. Cancer Immunol Immunother. 2011; 60(1): 87–97.
- Pai CC, Kuo TF, Mao SJ, Chuang TF, Lin CS, Chu RM. Immunopathogenic behaviors of canine transmissible venereal tumor in dogs following an immunotherapy using dendritic/tumor cell hybrid. Vet Immunol Immunopathol. 2011; 139(2–4): 187–99.
- Gyorffy S, Rodriguez-Lecompte JC, Woods JP, Foley R, Kruth S, Liaw PC, et al. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. J Vet Intern Med. 2005; 19(1): 56–63.
- Thacker EE, Nakayama M, Smith BF, Bird RC, Muminova Z, Strong TV, et al. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine. 2009; 27(50): 7116–24.
- Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood. 2004; 103(6): 2046–54.
- Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest. 1997; 100(11): 2757–65.
- Mason NJ, Coughlin CM, Overley B, Cohen JN, Mitchell EL, Colligon TA, et al. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma. Gene Ther. 2008; 15(13): 955–65.
- Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, Vonderheide RH, et al. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. PLoS One. 2011; 6(8): e24167.
